- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: example 3 [WO2015048662A2] | ICP-022 | ICP022
orelabrutinib is an approved drug (China (2020))
Compound class: Synthetic organic
Comment: The chemical structure that was submitted to the WHO for the INN orelabrutinib, is identical to the structure of example 3 that is claimed as a BTK inhibitor in patent WO2015048662A2 . The inhibitors in WO2015048662A2 are claimed for their potential to treat cancers  and inflammatory/autoimmune diseases that are mediated, at least in part, by Bruton's tyrosine kinase (BTK). Innocare Pharma have declared the ICP-022>orelabrutinib association on their company news webpage. Orelabrutinib is an orally administered, potent, irreversible and selective BTK-inhibitor.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Bond DA, Maddocks KJ. (2020)
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Hematol Oncol Clin North Am, 34 (5): 903-921. [PMID:32861286]
2. Chen X, Gao Y, Liu C, Ni H, Mulvihill M. (2015)
Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease.
Patent number: WO2015048662A2. Assignee: X-Rx Discovery, Inc.. Priority date: 03/09/2013. Publication date: 02/04/2015.
3. Dhillon S. (2021)
Orelabrutinib: First Approval.
Drugs, [Epub ahead of print]. DOI: 10.1007/s40265-021-01482-5 [PMID:33704654]